213 related articles for article (PubMed ID: 25912932)
21. Economic Analysis of Deep Brain Stimulation in Parkinson Disease: Systematic Review of the Literature.
Becerra JE; Zorro O; Ruiz-Gaviria R; Castañeda-Cardona C; Otálora-Esteban M; Henao S; Navarrete S; Acevedo JC; Rosselli D
World Neurosurg; 2016 Sep; 93():44-9. PubMed ID: 27216925
[TBL] [Abstract][Full Text] [Related]
22. Economic and Humanistic Burden of Osteoarthritis: A Systematic Review of Large Sample Studies.
Xie F; Kovic B; Jin X; He X; Wang M; Silvestre C
Pharmacoeconomics; 2016 Nov; 34(11):1087-1100. PubMed ID: 27339668
[TBL] [Abstract][Full Text] [Related]
23. [Social costs of the most common inflammatory rheumatic diseases in Mexico from the patient's perspective].
Mould-Quevedo J; Peláez-Ballestas I; Vázquez-Mellado J; Terán-Estrada L; Esquivel-Valerio J; Ventura-Ríos L; Aceves-Avila FJ; Bernard-Medina AG; Goycochea-Robles MV; Hernández-Garduño A; Burgos-Vargas R; Shumski C; Garza-Elizondo M; Ramos-Remus C; Espinoza-Villalpando J; Alvarez-Hernández E; Flores-Alvarado D; Rodríguez-Amado J; Casasola-Vargas J; Skinner-Taylor C;
Gac Med Mex; 2008; 144(3):225-31. PubMed ID: 18714591
[TBL] [Abstract][Full Text] [Related]
24. Out-of-pocket spending among a cohort of Australians living with gout.
Nathan N; Nguyen AD; Stocker S; Laba TL; Baysari MT; Day RO
Int J Rheum Dis; 2021 Mar; 24(3):327-334. PubMed ID: 32975889
[TBL] [Abstract][Full Text] [Related]
25. The importance of 'state-of-the-art' cost-of-illness studies. Comment on: The economic burden of gout: A systematic review.
Spaetgens B; Boonen A
Semin Arthritis Rheum; 2016 Feb; 45(4):e9. PubMed ID: 26170227
[No Abstract] [Full Text] [Related]
26. Frequency, risk, and cost of gout-related episodes among the elderly: does serum uric acid level matter?
Wu EQ; Patel PA; Mody RR; Yu AP; Cahill KE; Tang J; Krishnan E
J Rheumatol; 2009 May; 36(5):1032-40. PubMed ID: 19369467
[TBL] [Abstract][Full Text] [Related]
27. Economic burden of haematological adverse effects in cancer patients: a systematic review.
Liou SY; Stephens JM; Carpiuc KT; Feng W; Botteman MF; Hay JW
Clin Drug Investig; 2007; 27(6):381-96. PubMed ID: 17506589
[TBL] [Abstract][Full Text] [Related]
28. Economic impact of Juvenile Idiopathic Arthritis: a systematic review.
García-Rodríguez F; Gamboa-Alonso A; Jiménez-Hernández S; Ochoa-Alderete L; Barrientos-Martínez VA; Alvarez-Villalobos NA; Luna-Ruíz GA; Peláez-Ballestas I; Villarreal-Treviño AV; de la O-Cavazos ME; Rubio-Pérez N
Pediatr Rheumatol Online J; 2021 Oct; 19(1):152. PubMed ID: 34627296
[TBL] [Abstract][Full Text] [Related]
29. Scenarios to manage the hepatitis C disease burden and associated economic impact of treatment in Turkey.
Örmeci N; Malhan S; Balık İ; Ergör G; Razavi H; Robbins S
Hepatol Int; 2017 Nov; 11(6):509-516. PubMed ID: 29027109
[TBL] [Abstract][Full Text] [Related]
30. Cost-of-illness studies of diabetes mellitus: a systematic review.
Ng CS; Lee JY; Toh MP; Ko Y
Diabetes Res Clin Pract; 2014 Aug; 105(2):151-63. PubMed ID: 24814877
[TBL] [Abstract][Full Text] [Related]
31. The cost of schizophrenia: lessons from an international comparison.
Blomqvist AG; Léger PT; Hoch JS
J Ment Health Policy Econ; 2006 Dec; 9(4):177-83. PubMed ID: 17200594
[TBL] [Abstract][Full Text] [Related]
32. Cost of illness for bipolar disorder: a systematic review of the economic burden.
Kleine-Budde K; Touil E; Moock J; Bramesfeld A; Kawohl W; Rössler W
Bipolar Disord; 2014 Jun; 16(4):337-53. PubMed ID: 24372893
[TBL] [Abstract][Full Text] [Related]
33. [Cost of lost productivity in pharmacoeconomics analysis. Part I. A systematic review of the literature].
Wrona W; Hermanowski T; Golicki D; Jakubczyk M; Macioch T; Goszczyńska K; Wójcik R
Przegl Epidemiol; 2011; 65(1):147-52. PubMed ID: 21735852
[TBL] [Abstract][Full Text] [Related]
34. Economic burden of osteoporosis-related hip fracture in Asia: a systematic review.
Mohd-Tahir NA; Li SC
Osteoporos Int; 2017 Jul; 28(7):2035-2044. PubMed ID: 28314898
[TBL] [Abstract][Full Text] [Related]
35. A systematic review of low back pain cost of illness studies in the United States and internationally.
Dagenais S; Caro J; Haldeman S
Spine J; 2008; 8(1):8-20. PubMed ID: 18164449
[TBL] [Abstract][Full Text] [Related]
36. Indirect health costs in ulcerative colitis and Crohn's disease: a systematic review and meta-analysis.
Kawalec P; Malinowski KP
Expert Rev Pharmacoecon Outcomes Res; 2015 Apr; 15(2):253-66. PubMed ID: 25656310
[TBL] [Abstract][Full Text] [Related]
37. The economic burden of gout on an employed population.
Brook RA; Kleinman NL; Patel PA; Melkonian AK; Brizee TJ; Smeeding JE; Joseph-Ridge N
Curr Med Res Opin; 2006 Jul; 22(7):1381-9. PubMed ID: 16834837
[TBL] [Abstract][Full Text] [Related]
38. Economic impact of lower-limb osteoarthritis worldwide: a systematic review of cost-of-illness studies.
Salmon JH; Rat AC; Sellam J; Michel M; Eschard JP; Guillemin F; Jolly D; Fautrel B
Osteoarthritis Cartilage; 2016 Sep; 24(9):1500-8. PubMed ID: 27034093
[TBL] [Abstract][Full Text] [Related]
39. Cost of arthritis: a systematic review of methodologies used for direct costs.
Lo TK; Parkinson L; Cunich M; Byles J
Expert Rev Pharmacoecon Outcomes Res; 2016; 16(1):51-65. PubMed ID: 26618446
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
